E. Januszewicz - Concepedia

Author

E. Januszewicz

Also Known As

E H Januszewicz, E Henry Januszewicz, E Januszewicz, E. H. JANUSZEWICZ, E. H. Januszewicz, E. Henry Januszewicz, E. Januszewicz, E.H. Januszewicz, E.Henry Januszewicz, Elchanan H. Januszewicz

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne St Vincent's Hospital Melbourne Monash Medical Centre The Alfred Hospital

About

E. Januszewicz is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	17	768
2	Cell Biology	7	7	405
3	Health Sciences	6	6	312
4	Public Health	1	1	67
5	Blood Transplantation	1	1	67

E. Januszewicz

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
ALTERED TRANSCRIPTION OF AN ONCOGENE IN CHRONIC MYELOID LEUKAEMIA Eli Canaani, D. Steiner-Saltz, E Aghai, The Lancet Hematological MalignancyChromatinTranscriptional RegulationMixed-phenotype Acute LeukemiaHematology	1984	154
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma Chan Y. Cheah, Kirsten Herbert, Kacey O’Rourke, British Journal of Cancer	2014	129
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy Dennis Carney, David Westerman, Constantine S. Tam, Leukemia Hematological MalignancyFludarabine Combination ChemotherapyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2010	105
Inhibition by retinoic acid of myeloid progenitors in chronic myeloid leukemia and myeloproliferative disease: increased sensitivity in blastic phase of chronic myeloid leukemia E. Januszewicz, Esther Rabizadah, Zipora Maimon, Pathology Hematological MalignancyIncreased SensitivityChronic Myeloid LeukemiaMedicineMixed-phenotype Acute Leukemia	1988	96
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma Constantine S. Tam, Max Wolf, H. Miles Prince, Cancer	2006	94
BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration Lynda J. Campbell, Crisoula Patsouris, Kathleen C. Rayeroux, Cancer Genetics and Cytogenetics Hematological MalignancyTumor BiologyMedicineMixed-phenotype Acute LeukemiaImmunology	2002	73
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older Linda Mileshkin, John F. Seymour, M. Wolf, Leukemia & lymphoma/Leukemia and lymphoma Cell TherapyCardiovascular ToxicityHematological MalignancyOncologyStem Cell Transplantation	2005	67
Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma Susan Chua, John F. Seymour, Jacqui Streater, Leukemia & lymphoma/Leukemia and lymphoma Surgical OncologyIntermediate-grade Non-hodgkinPathologyEffective ProphylaxisMetronomic Chemotherapy	2002	61
Emergence of central nervous system myeloma in the era of novel agents Shane Gangatharan, Dennis Carney, H. Miles Prince, Hematological Oncology ImmunologyPathologyGliomaCns MmNovel Agents	2011	48
Fludarabine Combination Therapy Is Highly Effective in First-Line and Salvage Treatment of Patients with Waldenström's Macroglobulinemia Constantine S. Tam, Max Wolf, David Westerman, Clinical Lymphoma & Myeloma MedicineFludarabine Combination TherapySalvage TreatmentClinical TrialsPathology	2005	40

Page 1